Company profile
Seaport Therapeutics, Inc.
NASDAQ:SPTXBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07065240 | phase2 | recruiting | 2025-06-19 | 2027-03-01 | Seaport Therapeutics | A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) |
| NCT07161700 | phase2 | enrolling_by_invitation | 2025-09-02 | 2027-05-01 | Seaport Therapeutics | An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) |
FDA applications (0)
No records yet.